康氏抗纤方联合干扰素、利巴韦林治疗慢性丙型肝炎33例临床观察  

Clinical Observation on Kangshi Kangxian Formula Combined with Interferon and Ribavirin in 33 Cases of Chronic Hepatitis C

作　　者：梁惠卿[1,2] 杨嘉恩[2] 唐金模[2] 吴春城[2] 陈少东[1] 林莉[1] 

机构地区：[1]厦门大学医学院 [2]厦门市中医院肝病中心

出　　处：《中医杂志》2014年第23期2011-2015,共5页Journal of Traditional Chinese Medicine

基　　金：福建省卫生厅青年科研课题基金资助项目(2012-2-105)

摘　　要：目的观察康氏抗纤方联合聚乙二醇化干扰素α-2a(PEG-IFNα-2a)、利巴韦林对慢性丙型肝炎(CHC)患者抗病毒治疗应答及生活质量的影响。方法选择CHC患者64例,随机分为治疗组33例与对照组31例。对照组给予PEG-IFNα-2a注射液180μg/次,皮下注射,每周1次;利巴韦林0.3 g/次,口服,每天3次。治疗组在对照组基础上口服康氏抗纤方,每日1剂。两组均治疗24周。观察两组患者治疗前后肝组织病理、肝纤维化瞬时弹性测定值、血清丙氨酸氨基转氨酶(ALT)水平、丙肝病毒定量(HCV RNA)及慢性肝病问卷(CLDQ)积分的变化。结果两组患者病毒学应答与生化应答比较差异无统计学意义(P>0.05)。治疗后两组肝脏炎症及纤维化程度均较本组治疗前显著改善(P<0.05);治疗组改善肝纤维化程度方面显著优于对照组(P<0.05);治疗组治疗后肝纤维化瞬时弹性测定值改善程度显著优于对照组(P<0.05)。治疗组治疗后CLDQ各项积分与治疗前比较均明显提高(P<0.01),而对照组仅在系统症状、活动能力和情感方面得分明显提高(P<0.05),治疗组治疗后在腹部症状、困乏、情感、焦虑方面积分改善程度明显优于对照组(P<0.01)。结论康氏抗纤方联合PEG-IFNα-2a、利巴韦林治疗CHC在抗病毒治疗应答的同时,具有显著改善肝纤维化的程度及提高患者生活质量的作用。Objective To observe the influence on patient＇s response to antiviral therapy and quality of life using combined treatment of Kangshi Kangxian Formula, pegylated interferon-alpha-2a （PEG-IFNa-2a） and ribavirin for chronic hepatitis C （CHC）. Methods Totally 64 selected CHC patients were randomly divided ihto treatment group with 33 cases and control group with 31 cases Control group was given PEG-IFNo-2a subcutaneous injection 180 p,g each time, once per week and ribavirin orally 0. 3 g each time, 3 times per day. Treatment group had Kangshi Kangxian Formula orally, 1 dose per day, with the basic treatment same as control group. Treatment lasted for 24 weeks. The changes of liver tissue biopsy, hepatic fibrosis instantaneous elastic （FibroScan） value, serum alanine aminotransferase （ALT）, quantitative of hepatitis C virus （HCV RNA） and chronic liver disease questionnaire （CLDQ） scores were recorded after treatments of both groups Results Two groups＇ responses of virology and bio- chemistry showed no statistical significance （ P 〉 0.05 ） . Inflammation and fibrosis of the liver were signifi6antl improved after treatment （ P 〈 0.05 ） compared within each group before Improvement of liver fibrosis in treatment group is greater than control group （P 〈 0. 05）. On the improvement of FibroScan value, treatment group was obviously better than control group （ P 〈 0.05 ）. Every aspect of CLDQ scores of treatment group had different levels of in- creases （P 〈0. 01 ）, while control group only had some increases on systemic symptom, activity ability and emotion scores （P 〈0.05）. After treatment, treatment group＇s CLDQ scores on abdomenal pain, sleepinese, emotion and anxiety were notedly better than contreol group （P 〈 0. 01 ）. Conclusion Using Kangshi Kangxian Formula combined with PEG-IFNa-2a and ribavirin to treat CHC not only increased patient＇s response to antiviral therapy, but also improve the condition of liver fibrosis and patient＇s quality of

关 键 词：慢性丙型肝炎 肝纤维化 生活质量 康氏抗纤方 

分 类 号：R512.63[医药卫生—内科学]